--- title: Does drospirenone hormone therapy reduce weight gain and PMS-like symptoms? description: In studies of drospirenone-containing hormone therapy, women had less or no weight gain (mean decrease of 1.2 kg after one year) and improvements in bloating, url: https://niyora.com/research/papers/added-benefits-of-drospirenone-for-compliance-2005/ --- - [Niyora](https://niyora.com/) - [Research](https://niyora.com/research/) - [Library](https://niyora.com/research/library/) - Does drospirenone hormone therapy reduce weight gain and PMS-like symptoms? Survey study, 2005 # Does drospirenone hormone therapy reduce weight gain and PMS-like symptoms? In studies of drospirenone-containing hormone therapy, women had less or no weight gain (mean decrease of 1.2 kg after one year) and improvements in bloating, swelling, breast tenderness, and mood. Early or limited evidence Women in hormone replacement therapy or oral contraceptive clinical studies (review of prior research) ## What they did Review of clinical studies examining hormone therapies containing drospirenone. Studies measured effects on body weight and fluid-related symptoms. ## What they found Women on 1 mg estradiol with 2 mg drospirenone had mean body weight decrease of 1.2 kg after 1 year (p less than 0.001), compared to weight gain with estradiol alone. Improvements were seen in breast tenderness, swelling, abdominal bloating, skin changes, fatigue, and depressive mood. ## What it means for you Drospirenone may help prevent weight gain and improve fluid-related symptoms compared to other hormone therapies, which could improve quality of life. This review summarizes earlier studies but provides limited new primary evidence. A larger, more rigorous study would strengthen the findings. 1.2 kg Mean weight decrease after 1 year p < 0.001 Statistical significance 1 mg / 2 mg Estradiol and drospirenone dose ## About the study Original title Added benefits of drospirenone for compliance Authors Foidart JM Journal Climacteric : the journal of the International Menopause Society Year 2005 Study design Survey study Participants 2 What was tested Drospirenone-containing hormone therapies compared to other formulations. Read the paper [doi.org/10.1080/13697130500330309](https://doi.org/10.1080/13697130500330309) ## Topics [Premenstrual syndrome (PMS)](https://niyora.com/research/topics/condition-pms/)[Menstrual cycle and mood](https://niyora.com/research/topics/condition-cycle-mood/)[Bloating, breast tenderness and physical symptoms](https://niyora.com/research/topics/symptom-physical-symptoms/)[Oral contraceptives and drospirenone](https://niyora.com/research/topics/treatment-hormonal-contraceptives/)[Estradiol, progesterone and hormone therapy](https://niyora.com/research/topics/treatment-hormone-therapy/)[Quality of life and daily functioning](https://niyora.com/research/topics/life-area-quality-of-life/) Research tells you what helps on average. Niyora helps on the day it hits. Calm down, see it another way, and decide what to say, with a PMS and PMDD app built by a doctor. ## Related studies Review, 2009 What causes PMDD and what are the treatment options? Study, 2025 What causes PMS and what are the main treatment options? Case report, 2023 Can stopping ovulation help severe PMDD when other treatments do not work? Study, 2022 What are the symptoms, causes, and treatments of PMS and PMDD? Systematic review, 2023 What hormonal treatments have been tested for PMDD, menstrual migraine, and catamenial epilepsy? Survey study, 2022 What causes PMS and PMDD and what new treatments are being studied? Ask AI about this page Copy prompt ChatGPT ↗ Claude ↗ Perplexity ↗ Google AI Mode ↗ Grok ↗